share_log

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K:重大事件
美股sec公告 ·  07/30 16:06
Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. has been granted a 180-day extension by the Nasdaq Stock Market LLC to meet the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The extension, which lasts until November 18, 2024, follows the company's non-compliance notice received on May 20, 2024, due to its reported negative stockholders' equity of $112.5 million as of March 31, 2024. Avalo Therapeutics had submitted a plan of compliance to Nasdaq's Listing Qualifications Department in response to the notice. While the extension provides additional time for Avalo Therapeutics to regain compliance, there is no guarantee that the company will meet the Nasdaq's Listing Rule by the new deadline.
Avalo Therapeutics, Inc. has been granted a 180-day extension by the Nasdaq Stock Market LLC to meet the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The extension, which lasts until November 18, 2024, follows the company's non-compliance notice received on May 20, 2024, due to its reported negative stockholders' equity of $112.5 million as of March 31, 2024. Avalo Therapeutics had submitted a plan of compliance to Nasdaq's Listing Qualifications Department in response to the notice. While the extension provides additional time for Avalo Therapeutics to regain compliance, there is no guarantee that the company will meet the Nasdaq's Listing Rule by the new deadline.
Avalo Therapeutics,Inc.已获得纳斯达克证券交易所LLC的180天延期,以满足继续在纳斯达克资本市场上市的最低股东权益要求。该延期将持续到2024年11月18日,此前该公司于2024年3月31日报告净负债为11250万美元而收到不合规通知。Avalo Therapeutics已向纳斯达克上市资格部门提交了符合计划以响应该通知。虽然该延期为Avalo Therapeutics提供了额外时间来恢复符合标准,但并不能保证该公司将在新期限前满足纳斯达克上市规则。
Avalo Therapeutics,Inc.已获得纳斯达克证券交易所LLC的180天延期,以满足继续在纳斯达克资本市场上市的最低股东权益要求。该延期将持续到2024年11月18日,此前该公司于2024年3月31日报告净负债为11250万美元而收到不合规通知。Avalo Therapeutics已向纳斯达克上市资格部门提交了符合计划以响应该通知。虽然该延期为Avalo Therapeutics提供了额外时间来恢复符合标准,但并不能保证该公司将在新期限前满足纳斯达克上市规则。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息